Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05020444 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

TriPRIL CAR T Cells in Multiple Myeloma

StatusActive, Not Recruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Enrollment reduced 11% 18 → 16 participants
See other at-risk trials from Marcela V. Maus, M.D.,Ph.D.

Record History

  1. Enrollment closed, study ongoing Enrollment reduced: 18 → 16 participants · Site details revisedv11 Show 2 more changesShow less
    • Enrollment reduced: 18 → 16 participants
    • Site details revised
  2. Primary completion pushed from Mar 31, 2026 to Feb 24, 2028 Completion moved earlier from Mar 31, 2028 to Feb 24, 2028v10 Show 1 more changeShow less
    • Completion moved earlier from Mar 31, 2028 to Feb 24, 2028
  3. Primary completion date: Jan 1, 2026 to Mar 31, 2026 Completion date: Jan 1, 2028 to Mar 31, 2028v9 Show 1 more changeShow less
    • Completion date: Jan 1, 2028 to Mar 31, 2028
  4. Eligibility criteria shortened, about 16 wordsv8 See this version in full on ClinicalTrials.gov ↗
  5. Site contact updatedv7
Show 5 earlier versionsHide 5 earlier versions
  1. Primary completion date: Jan 1, 2024 to Jan 1, 2026 Completion date: Jan 1, 2025 to Jan 1, 2028v6 Show 1 more changeShow less
    • Completion date: Jan 1, 2025 to Jan 1, 2028
  2. Primary completion date: Jan 1, 2023 to Jan 1, 2024 Completion date: Jan 1, 2024 to Jan 1, 2025v5 Show 1 more changeShow less
    • Completion date: Jan 1, 2024 to Jan 1, 2025
  3. Re-verified, no change to tracked fieldsv4
  4. Start date changed from estimate of Sep 2021 to Oct 5, 2021v3
  5. Trial status: Not Yet Recruiting to Recruiting Start date: Jan 2022 to Sep 2021 · Site details revisedv2 Show 2 more changesShow less
    • Start date: Jan 2022 to Sep 2021
    • Site details revised
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This research study involves the study of TriPRIL CAR T Cells for treating people with relapsed or refractory multiple myeloma and to understand the side effects when treated with TriPRIL CAR T Cells. This research study involves the study drugs:. * TriPRIL CAR T Cells * Fludarabine and Cyclophosphamide: Standardly used chemotherapy drugs as part of lymphodepleting process
Trial Details
NCT Number NCT05020444
Lead Sponsor Marcela V. Maus, M.D.,Ph.D.
Conditions Multiple Myeloma, Multiple Myeloma in Relapse, Refractory Multiple Myeloma
Enrollment 16 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov